Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids
- PMID: 1645605
- DOI: 10.1007/BF01806369
Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids
Abstract
This study was designed to assess the multiple steroid receptor mediated activities of a series of synthetic 'progestins' on breast cancer cell growth, using the human ZR-75-1 cell line which possesses functional estrogen (ER), androgen (AR), and glucocorticoid (GR) receptors as well as progesterone (PgR) receptors. Four 17-hydroxyprogesterone derivatives (chlormadinone acetate, CMA; cyproterone acetate, CPA; medroxyprogesterone acetate, MPA; and megestrol acetate, MGA) and two 19-nortestosterone derivatives (norethindrone, NRE, and norgestrel, NRG) were thus investigated. Based on the requirement of estrogens for PgR-mediated antiproliferative effects and the reversal of PgR-mediated action by insulin, it was found that although all 'progestins' could inhibit ZR-75-1 cell growth through the PgR at low concentrations, the relative contribution of this receptor in cell growth control is highly variable between compounds. The quantitative importance of PgR-mediated inhibition of cell proliferation was inversely related to the amplitude of the androgenic effects induced by the compounds, the AR-mediated effects increasing in the order CPA less than MGA less than CMA less than NRE less than NRG less than MPA. The specificity of these androgenic effects is further supported by their reversal upon addition of the antiandrogen hydroxyflutamide. In addition, the 17-hydroxyprogesterone derivatives, but not the 19-nortestosterone derivatives, had glucocorticoid activities at high (micromolar) concentrations, as shown by reversal of growth inhibition by the antagonist RU486 in the presence of saturating concentrations of 5 alpha-dihydro-testosterone. All 'progestins' tested, except MPA and NRE, also had some antiglucocorticoid activity, NRG being the most potent in this respect. Finally, NRE and NRG exerted a marked mitogenic effect in estrogen-free medium which was clearly mediated through the ER as shown by the competitive reversal of their action by the steroidal antiestrogen EM-139. The present results show that growth measurements of the human breast cancer cells ZR-75-1 permit, with the appropriate steroid additions, the assay of progestin, androgen, estrogen, and glucocorticoid agonistic as well as antagonistic activities of test compounds. The present study shows, somewhat surprisingly, that while the AR is almost completely responsible for the action of MPA at low concentrations, the majority of the action of NRE, NRG, and MGA is also exerted through AR, while the androgenic action of CPA plays a lower role in the growth inhibition induced by this compound.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.Breast Cancer Res Treat. 1989 Mar;13(2):161-72. doi: 10.1007/BF01806528. Breast Cancer Res Treat. 1989. PMID: 2525057
-
Effects of antiandrogenic progestins, chlormadinone and cyproterone acetate, and the estrogen 17α-ethinylestradiol (EE2), and their mixtures: Transactivation with human and rainbowfish hormone receptors and transcriptional effects in zebrafish (Danio rerio) eleuthero-embryos.Aquat Toxicol. 2017 Jan;182:142-162. doi: 10.1016/j.aquatox.2016.11.001. Epub 2016 Nov 9. Aquat Toxicol. 2017. PMID: 27907851
-
Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells.Ann N Y Acad Sci. 1990;595:130-48. doi: 10.1111/j.1749-6632.1990.tb34288.x. Ann N Y Acad Sci. 1990. PMID: 2142871
-
The estrogenic activity of synthetic progestins used in oral contraceptives.Cancer. 1993 Feb 15;71(4 Suppl):1501-5. doi: 10.1002/cncr.2820710415. Cancer. 1993. PMID: 8431886 Review.
-
An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells.J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):111-22. doi: 10.1016/j.jsbmb.2003.08.003. J Steroid Biochem Mol Biol. 2003. PMID: 14672731 Review.
Cited by
-
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.Breast Cancer Res. 2005;7(6):R1036-50. doi: 10.1186/bcr1340. Epub 2005 Nov 2. Breast Cancer Res. 2005. PMID: 16457685 Free PMC article.
-
Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression.Cancer Metastasis Rev. 2022 Dec;41(4):803-832. doi: 10.1007/s10555-022-10047-1. Epub 2022 Jun 27. Cancer Metastasis Rev. 2022. PMID: 35761157 Free PMC article. Review.
-
Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice.Br J Pharmacol. 2009 Dec;158(8):1951-60. doi: 10.1111/j.1476-5381.2009.00470.x. Br J Pharmacol. 2009. PMID: 20050187 Free PMC article.
-
Role of the androgen receptor in human breast cancer.J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103. doi: 10.1023/a:1018730519839. J Mammary Gland Biol Neoplasia. 1998. PMID: 10819508 Review.
-
Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.Breast Cancer Res Treat. 1995 Mar;33(3):237-44. doi: 10.1007/BF00665948. Breast Cancer Res Treat. 1995. PMID: 7749151
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials